Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Gone Too Hard? Regular Erectile Dysfunction Drug Use Raises Risk of Vision Loss, Study Finds : ScienceAlert (opens in a new tab)

sciencealert.com · 2026-09-11

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 4 supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1

The story

Gone Too Hard? Regular Erectile Dysfunction Drug Use Raises Risk of Vision Loss, Study Finds : ScienceAlert

sciencealert.com · 2026-09-11

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

Mostly supported

Every claim we could check holds up. Four of five claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

  • 4 supported
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredThe article says the study was observational and could not prove tadalafil caused the extra glaucoma cases; it also notes limitations such as coded diagnoses, no direct eye measurements, and possible detection bias.View evidenceHide evidence

Why this verdict

The observational, retrospective EHR-based design is supported by the abstract profile, so the caution that the study cannot prove causation is appropriate. However, the specific limitations listed in the story—coded diagnoses, no direct eye measurements, and possible detection bias—are not detailed in the abstract profile. They may be full-paper limitations, but they are not verifiable at the supplied abstract evidence depth.

1

Study evidence

Tadalafil use versus non-PDE5i use associated with higher hazard of incident glaucoma over up to 5 years.HR 1.22 (95% CI 1.12 to 1.33)

“This multinational, retrospective cohort study was conducted using the TriNetX database.”
2

Study evidence

Tadalafil use was associated with increased hazard of ocular hypertension in the matched cohort.HR 1.32 (95% CI 1.06 to 1.65)

“Hazard ratios (HRs) were estimated for incident glaucoma of different subtypes and initiation of glaucoma treatment.”
Claim 2 of 5SupportedA new study linked long-term tadalafil use to an increased risk of glaucoma, a group of eye diseases where optic nerve damage causes vision loss.View evidenceHide evidence

As stated22 percent increase in relative risk; about 77 additional diagnoses for every 10,000 men

Why this verdict

The abstract-profile evidence supports the central associational claim: in a retrospective matched cohort, tadalafil use for LUTS in men aged ≥40 was associated with higher incident glaucoma risk, HR 1.22 (95% CI 1.12–1.33), with 5-year cumulative incidence 3.93% vs 3.16%. The story frames this as a link rather than causation. At abstract depth, exposure duration details underlying the phrase “long-term” are not fully specified, but the core risk association and magnitude are supported.

1

Study evidence

Tadalafil use versus non-PDE5i use associated with higher hazard of incident glaucoma over up to 5 years.HR 1.22 (95% CI 1.12 to 1.33)

“This multinational, retrospective cohort study was conducted using the TriNetX database.”
Claim 3 of 5SupportedThe study focused on men over 40 who regularly took tadalafil for urinary symptoms, and compared them with matched men who had not used a drug from the same family.View evidenceHide evidence

As stated36,927 men in each group

Why this verdict

The profile states the cohort included men aged ≥40 with lower urinary tract symptoms, comparing tadalafil users with non-PDE5i users after 1:1 propensity-score matching. The matched sample size was 36,927 per group. The word “regularly” is more specific than the abstract-profile exposure description, but the main population, exposure, comparator, and sample size are supported.

1

Study evidence

Tadalafil use versus non-PDE5i use associated with higher hazard of incident glaucoma over up to 5 years.HR 1.22 (95% CI 1.12 to 1.33)

“This multinational, retrospective cohort study was conducted using the TriNetX database.”
Claim 4 of 5SupportedOver five years, glaucoma occurred in 3.93 percent of tadalafil users versus 3.16 percent of non-users, and the same pattern appeared for high eye pressure, primary open-angle glaucoma, or starting glaucoma treatment.View evidenceHide evidence

As statedroughly four of every 100 users versus about three of every 100 non-users

Why this verdict

The profile reports 5-year cumulative incidence of glaucoma of 3.93% in tadalafil users versus 3.16% in non-users, and elevated hazards for ocular hypertension, primary open-angle glaucoma, and initiation of glaucoma treatment. The story’s approximate absolute framing is consistent with those abstract-level results.

1

Study evidence

Tadalafil use versus non-PDE5i use associated with higher hazard of incident glaucoma over up to 5 years.HR 1.22 (95% CI 1.12 to 1.33)

“This multinational, retrospective cohort study was conducted using the TriNetX database.”
2

Study evidence

Tadalafil use was associated with increased hazard of ocular hypertension in the matched cohort.HR 1.32 (95% CI 1.06 to 1.65)

“Hazard ratios (HRs) were estimated for incident glaucoma of different subtypes and initiation of glaucoma treatment.”
Claim 5 of 5SupportedThe study did not find a significant increase for low-tension glaucoma or primary angle-closure glaucoma.View evidenceHide evidence

Why this verdict

The abstract-profile evidence explicitly states that no significant associations were found for low-tension glaucoma or primary angle-closure glaucoma.

1

Study evidence

Tadalafil use versus non-PDE5i use associated with higher hazard of incident glaucoma over up to 5 years.HR 1.22 (95% CI 1.12 to 1.33)

“This multinational, retrospective cohort study was conducted using the TriNetX database.”
2

Study evidence

Tadalafil use was associated with increased hazard of ocular hypertension in the matched cohort.HR 1.32 (95% CI 1.06 to 1.65)

“Hazard ratios (HRs) were estimated for incident glaucoma of different subtypes and initiation of glaucoma treatment.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Robustness analyses: results reportedly remained robust to 1-, 3-, and 6-month lag-time sensitivity analyses and were consistent in selected subgroups.

    The supplied story claims and caveats do not mention the subgroup consistency or lag-time robustness analyses reported in the abstract profile.

    From Retrospective propensity-score matched cohort (TriNetX); Retrospective propensity-score matched cohort (TriNetX)

  • Authors’ interpretation: ophthalmic evaluation or follow-up may be considered, particularly for patients with glaucoma risk factors.

    The supplied story presentation says patients should not stop prescribed tadalafil without speaking to a doctor, but it does not include the paper-profile statement about considering ophthalmic evaluation/follow-up for higher-risk patients.

    From Retrospective propensity-score matched cohort (TriNetX); Retrospective propensity-score matched cohort (TriNetX)

7 things the story did carry across
  • Study design and data source: multinational retrospective cohort using TriNetX EHR data, with propensity-score matching.
  • Population and exposure: men aged ≥40 with LUTS, tadalafil users compared with non-PDE5i users.
  • Primary finding: tadalafil use was associated with higher incident glaucoma risk, HR 1.22, with 5-year cumulative incidence 3.93% vs 3.16%.
  • Secondary outcome findings: elevated risks for ocular hypertension, primary open-angle glaucoma, and initiation of glaucoma treatment.
  • Null subtype findings: no significant association for low-tension glaucoma or primary angle-closure glaucoma.
  • Causal limitation: the evidence is observational and retrospective, so it supports association rather than proof that tadalafil causes glaucoma.
  • Abstract-level limitations: details on exposure duration/dose, outcome definitions, covariate balance diagnostics, and outcome validation are not provided in the abstract profile.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEstimate whether tadalafil use for LUTS is associated with increased incident glaucoma risk versus non-PDE5i use in men aged ≥40 years.Retrospective propensity-score matched cohort (TriNetX)Expand

In plain English

Multinational retrospective cohort study using TriNetX EHR data (2012–2022) of men ≥40 years with LUTS comparing tadalafil users versus non-PDE5i users. After 1:1 propensity-score matching (age, race, comorbidities, renal function, concomitant medications), tadalafil use was associated with a higher hazard of incident glaucoma over up to 5 years (HR 1.22; 95% CI 1.12–1.33). Elevated risks were reported for ocular hypertension, primary open-angle glaucoma, and initiation of glaucoma treatment; no significant associations were reported for low-tension or primary angle-closure glaucoma. The analysis reported matched cohort sizes (36,927 per group), 5-year cumulative incidence (3.93% vs 3.16%; p<0.001), and robustness to 1-, 3- and 6-month lag-time sensitivity analyses.

Key findings

  • Tadalafil use versus non-PDE5i use associated with higher hazard of incident glaucoma over up to 5 years.HR 1.22 (95% CI 1.12 to 1.33)
  • Elevated risk observed for ocular hypertension among tadalafil users.HR 1.32 (95% CI 1.06 to 1.65)
“This multinational, retrospective cohort study was conducted using the TriNetX database.”
What this piece can’t prove

2 further details could not be confirmed from the summary.

2secondary dataCharacterize which glaucoma-related outcomes/subtypes (eg, ocular hypertension, POAG, treatment initiation) show associations and assess robustness across subgroups and lag-time sensitivity analyses.Retrospective propensity-score matched cohort (TriNetX)Expand

In plain English

Within a multinational, propensity-score matched TriNetX cohort of men ≥40 with lower urinary tract symptoms (2012–2022), the authors report subtype-specific associations between tadalafil use and incident glaucoma and examine robustness across subgroups and lag-time sensitivity analyses. In matched analyses up to 5 years, tadalafil use was associated with elevated hazards for ocular hypertension, primary open-angle glaucoma, and initiation of glaucoma treatment, while no associations were reported for low-tension or primary angle-closure glaucoma. The abstract states these findings were consistent in men >50 years, the white population, and across comorbidities and remained robust to 1-, 3- and 6-month lag-time analyses.

Key findings

  • Tadalafil use was associated with increased hazard of ocular hypertension in the matched cohort.HR 1.32 (95% CI 1.06 to 1.65)
  • Tadalafil use was associated with increased hazard of primary open-angle glaucoma (POAG).HR 1.33 (95% CI 1.05 to 1.67)
“Hazard ratios (HRs) were estimated for incident glaucoma of different subtypes and initiation of glaucoma treatment.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Tadalafil improves lower urinary tract symptoms in patients with benign prostatic hyperplasia,

Inpharma Weekly · 2005 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.